Mexico Healthcare and Life Sciences Report 2015 released by Pharmaboardroom

Nov 30 2015

Pharmaboardroom releases its new 98-page Mexico Healthcare and Life Sciences Report 2015.

It offers companies, investors, policymakers, and stakeholders with an interest in healthcare, pharmaceuticals, or life sciences insights into the second largest pharma and healthcare market in Latin America, a country of over 122 million people.

It features interviews with senior executives from the major companies in Mexico and leaders of the country's most important institutions, updated facts and figures on Mexico's healthcare and pharma sectors, and feature stories.

The report is an authoritative assessment of a fast-growing sector in a country likely to continue receiving a great deal of investment in the years and decades ahead, for the following reasons:

Reform - The Mexican government has committed to turn Mexico from a manufacturing to an innovation-centric economy, with healthcare as a key driver. For example, the recent opening of the Mexican Social Security Institute to clinical research will to open the country up to more innovation.

International Recognition - Mexico's regulatory authority, Cofepris, has been recognized as a National Regulatory Authority of Regional Reference for medicines and biological products by the Pan-American Health Organization and as a Functional Regulatory Agency for vaccines by the World Health Organization.

Increased Coverage - In the last decade, Mexico has moved rapidly towards universal healthcare coverage. The number of interventions covered by Seguro Popular has increased threefold in the last decade, the amount of drugs included more than 300 percent, and the number of diseases included in the 'fund for protection against catastrophic expenditures' raised from 4 to 59.

The Mexico Healthcare and Life Sciences Report 2015 includes features and articles on:

• Industry Trends including Mexico's strength in genomics, decreasing approval times, innovation, foreign companies in Mexico, generics, manufacturing costs, multinationals, biotech, the Mexican medical devices industry, pharmacies offering medical consultation, and physicians at the point of sale, third party logistics
• Institutions and Reforms including Cofepris - Mexico's Regulator, Mexico's Healthcare System, Social Security System, and drive towards Universal Healthcare Coverage.
• Healthcare Trends including the rise of the non-communicable disease, access challenges, the battle against rare diseases, and mental health in Mexico,
• Macroeconomic and legal trends such as the market outlook and intellectual property in Mexico

Interviews

The report also includes interviews with:

• Julio Frenk, Harvard TH Chan School of Public Health
• Rafael Gual, Canifarma
• Cristobál Thompson, AMIIF
• Roberto Tapia, Carlos Slim Foundation
• Alexis Serlin, Novartis Mexico
• José Alarcón Irigoyen, PriceWaterhouseCoopers
• Juan Knobloch, Knobloch Information Group
• Fabiola Trigueros, Smart Scale
• Mark Stoffels, Philips Healthcare Mexico
• Teresa Corona Vazquez, Instituto Nacional de Neurología y Neurocirugía
• Juan Ángeles Uribe, Carnot
• Sonia Mayra Pérez Tapia, Udimeb
• Mauricio Bravo, Tornel
• Dominik Bacher, director of Bacher Zoppi
• Alfredo Gutierrez, Anfitriones

Quotes

"Competition is fierce, but the market as well as the regulatory framework in place provide the necessary certainty to keep investing in Mexico." - Ugo de Jacobis, president and general director of AstraZeneca Mexic

"The main reasons that lead the company to pick Mexico over other countries is the strong commitment of the Mexican government to public health, and specifically to vaccination." - Eduardo Arce Parellada, Sanofi Pasteur Mexico

"We support increased participation of the private sector in the health sector through outsourcing of services and public-private partnerships. But there are still many questions about how this should happen." - José Campillo, President of the Mexican Health Foundation (Funsalud)

"Mexican drug manufacturers are investing in the country and are fighting for it, and this should be recognized at national and international level." - Alfredo Rimoch, general director of Liomont

SOURCE Pharmaboardroom.com